European regulators have approved an update to the product information for Sanofi Pasteur MSD’s cervical cancer jab Gardasil, to include new long-term data on protection against four strains of the Human papillomavirus.

The Summary of Product characteristics (SmPC) for Gardasil will include immunogenicity and effectiveness data showing sustained protection against HPV 6, 11, 16 and 18 disease, the group said.

For more details, go to: http://www.pharmatimes.com/Article/14-09-15/EU_OKs_Gardasil_update_on_long-term_HPV_protection.aspx